Shravani Gangidi
Boston, MANPI 1962963900
Payments from drug & device makers
What this record shows
16 manufacturers reported payments, led by Medtronic at 34.2% of the total. 2025 is the largest year on record at $5,332, 2.5 times the $2,156 reported in 2022.
Across 146 payments — averaging $75.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$3K
- Biosense Webster, Inc.$2K
- Pfizer$736
- AstraZeneca$566
- Amgen$321
- plus $614 from 10 others
What the payments were for
- Travel & lodging$5,74352%
- Food & beverage$5,34048%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 34 | $3,786 |
| Boston Scientific | 7 | $2,890 |
| Biosense Webster, Inc. | 19 | $2,171 |
| Pfizer | 26 | $736 |
| AstraZeneca | 20 | $566 |
| Amgen | 13 | $321 |
| Daiichi Sankyo Inc. | 5 | $124 |
| Boehringer Ingelheim | 4 | $110 |
| Alnylam Pharmaceuticals Inc. | 4 | $82 |
| Merck | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 2 | $59 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Bayer | 2 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACCOLADE SR$2,890
- Carto 3$1,684
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 14 | $21,921 |
| FarxigaDapagliflozin Propanediol | 12 | $16,094 |
| Rosuvastatin Calcium | 29 | $1,218 |
| Metoprolol Succinate | 47 | $840 |
| Atorvastatin Calcium | 26 | $364 |
| Amlodipine Besylate | 18 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $110 | $21,92114 claims |
| AstraZenecaFarxiga | $566 | $16,09412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Massachusettson file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.